Ulisse Biomed S.p.A. (BIT:UBM)
Italy · Delayed Price · Currency is EUR 0.8580
+0.0080 (0.94%)
Aug 14, 2025, 11:09 AM CET
Dada Nexus Revenue
In the year 2024, Ulisse Biomed had annual revenue of 767.93K EUR with 1,059.87% growth. Ulisse Biomed had revenue of 397.07K in the half year ending December 31, 2024, with 431.07% growth.
Revenue
767.93K
Revenue Growth
+1,059.87%
P/S Ratio
27.10
Revenue / Employee
34.91K
Employees
22
Market Cap
20.81M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 767.93K | 701.72K | 1,059.87% |
| Dec 31, 2023 | 66.21K | -72.23K | -52.17% |
| Dec 31, 2022 | 138.44K | -142.00K | -50.64% |
| Dec 31, 2021 | 280.44K | -325.06K | -53.68% |
| Dec 31, 2020 | 605.50K | 594.63K | 5,469.84% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Recordati Industria Chimica e Farmaceutica | 2.48B |
| DiaSorin | 1.22B |
| Amplifon | 2.41B |
| EL.En. | 577.19M |
| Philogen | 77.65M |
| Safilo Group | 998.89M |
| GPI S.p.A. | 509.93M |
| Pharmanutra | 116.15M |